All Search Results
News Releases
Sep 30, 2026, 16:23 ET Huntington Bancshares Incorporated Announces Third Quarter 2026 Earnings Call Details
webcast in the Investor Relations section of Huntington's website or through a dial-in telephone number at (877) 407-8029 or (201) 689-8029; conference ID # 13762987.A replay of the webcast will be archived in the Investor Relations section of Huntington's website. A telephone replay will be available
More news about: Huntington Bancshares Incorporated
Sep 30, 2026, 10:00 ET Huntington Bank Announces Investments in United Housing, Boys & Girls Clubs of Greater Memphis to Support Families and Future Growth
are involved with United Housing through program sponsorships, volunteering, board service and first-time homebuyer education and seminars.Huntington's commitment to affordable housing is a core pillar in its broader community development strategy. Across its markets, the bank makes investments
More news about: Huntington Bancshares Incorporated
Sep 30, 2026, 08:30 ET Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust
More news about: Neurocrine Biosciences, Inc.
Sep 29, 2026, 20:12 ET uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)
uniQure's four-year AMT-130 Huntington's disease benefit came in smaller than its three-year result, and QURE shares plummeted. SueWallSt notifies investors of a pending investigation into potential securities law violations.NEW YORK, Sept.
More news about: SueWallSt.com
Sep 28, 2026, 16:05 ET Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer
endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust
More news about: Neurocrine Biosciences, Inc.
